Clinical Oncology
Volume 22, Issue 6 , Page 394 , August 2010

Thyroid Cancer: Evidence-based Optimal Management and the Search for a Cure

  • U.K. Mallick

      Affiliations

    • Corresponding Author InformationAuthor for correspondence: U.K. Mallick, Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK.

Received 29 April 2010 ,Accepted 4 May 2010.

References 

  1. Eliot TS. Choruses from “The Rock” 1934. In: Selected poems. Faber and Faber London; 1961;
  2. Cooper DS, Doherty GM, Haughen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214
  3. Cheng SY, Ringel MD. Frontiers in thyroid cancer. Thyroid. 2009;19(12):1297–1298
  4. Nikiforova MN, Nikiforov YE. Molecular diagnostics and predictors in thyroid cancer. Thyroid. 2009;19(12):1351–1361
  5. Damante G, Scaloni A, Tell G. Thyroid tumors: novel insights from proteomic studies. Expert Rev Proteomics. 2009;6(4):363–376
  6. Baril P, Martin-Duque P, Vassaux G. Visualization of gene expression in the live subject using the Na/I symporter as a reporter gene: applications in biotherapy. Br J Pharmacol. 2009;159(4):761–771
  7. Hingorani M, Spitzweg C, Vassaux G, et al. The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr Cancer Drug Targets. 2010;10(2):242–267
  8. Li W, Ain K. Human sodium/iodide symporter (hNIS) gene expression is inhibited by a trans-active transcriptional repressor, NIS-repressor, containing PARP-1 in thyroid cancer cells. Endocr Relat Cancer. 2010;17(2):383–398

PII: S0936-6555(10)00191-3

doi: 10.1016/j.clon.2010.05.019

Clinical Oncology
Volume 22, Issue 6 , Page 394 , August 2010

Article Tools